Asian-News.net is your go-to online destination for comprehensive coverage of major news across Asia. From politics and business to culture and technology, we bring you the latest updates, deep analyses, and critical insights from every corner of the continent. Featuring exclusive interviews, high-quality photos, and engaging videos, we keep you informed on the breaking news and significant events shaping Asia. Stay connected with us to get a 24/7 update on the most important stories and trends. Our daily updates ensure that you never miss a beat on the happenings in Asia's diverse nations. Whether it's a political shift in China, economic development in India, technological advancements in Japan, or cultural events in Southeast Asia, Asian-News.net has it covered. Dive into the world of Asian news with us and stay ahead in understanding this dynamic and vibrant region.

Contacts

  • <asian-news.net

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

The Food and Drug Administration on Tuesday approved Novo Nordisk's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular injection in the U.S. 

The drug is already widely used and covered to treat Type 2 diabetes. The FDA's decision means Ozempic can now be used to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in patients with both chronic kidney disease and diabetes.

The decision could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function and is one of the leading causes of death in the U.S. Around 37 million American adults are living with chronic kidney disease, according to Novo Nordisk.

Diabetes is a key risk factor for kidney disease. Roughly 40% of Type 2 diabetes patients have the condition, which can cause additional sickness such as increased risk of cardiovascular problems and death, Novo Nordisk said.

"All chronic kidney disease is progressive. It's a year-on-year, relentless decline in renal function," Stephen Gough, Novo Nordisk's global chief medical officer, said in an interview, referring to the kidney's ability to filter waste from the blood.

He noted that when the condition progresses to the point of kidney failure — also known as end-stage kidney disease — patients require long-term dialysis treatments to remove waste from the blood, or a kidney transplant. Both are burdensome, and death among patients with end-stage kidney disease is "very high," particularly from cardiovascular disease, according to Gough.

The approval also demonstrates that a blockbuster class of diabetes and weight loss drugs called GLP-1s have significant

Read more on cnbc.com
DMCA